New Drugs

Brand/Generic Company Description
Demylocan
decitabine
Pendopharm

IV pyrimidine analogue for treatment of myelodysplastic syndromes.

Idhifa
enasidenib
Celgene

An agent for relapsed/refractory acute myeloid leukemia with IDH2 mutation.

Influvac Tetra
influenza vaccine
BGP Pharma/Mylan

New quadrivalent formulation flu vaccine for adults.

Lorbrena
lorlatinib
Pfizer

An oral kinase inhibitor for ALK-positive metastatic non-small cell lung cancer.

Lutathera
lutetium (177Lu) oxodotreotide
Advanced Accelerator Apps.

IV radiopharmaceutical for gastroenteropancreatic neuroendocrine tumors.

Onstryv
safinamide
Valeo

An MAO-B inhibitor add-on therapy for "off" Parkinson's episodes in patients on stable doses of levodopa.

Oxervate
cenegermin
Dompé (Italy)

An ophthalmic recombinant human nerve growth factor for moderate or severe neurotrophic keratitis.

Vizimpro
dacomitinib
Pfizer

Oral pan-human epidermal growth factor receptor inhibitor for advanced/metastatic non-small cell lung cancer.

Vonvendi
von Willebrand factor, recombinant (vonicog alfa)
Shire

IV rVWF for treatment/control of bleeding episodes in von Willebrand disease.

Yescarta
axicabtagene ciloleucel
Gilead Sciences

A CD19-directed genetically modified autologous T cell immunotherapy for relapsed/refractory large B cell lymphoma.

Brand/Generic Company Description
Cystadrops
cysteamine HCl
Recordati Rare Diseases Canada

An ophthalmic cystine-depleting agent for corneal cystine crystal deposits in patients with cystinosis.

Envarsus PA
tacrolimus
Endo/Paladin Labs

A prolonged-release tablet formulation for prophylaxis of kidney or liver transplant rejection.

Renvela
sevelamer
Sanofi-Aventis

New oral suspension formulation for hyperphosphatemia in children.

Tolak
fluorouracil
Hill Dermaceuticals

New 4% topical cream formulation for actinic keratosis lesions of the face, ears, and scalp.

Brand/Generic Company Description